Federal Court of Appeal finds Minister of Health’s refusal to grant a CSP for SHINGRIX is reasonable

Published date29 April 2021
Subject MatterStandard of Review,Patents,Certificates of Supplementary Protection (CSPs),Pharmaceutical Industry,The Patent Act,Canada,Pharmaceutical Patents,Health Canada,Minister of Health,CETA,Appeals
AuthorDaphne Lainson
Law FirmSmart & Biggar

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT